Iron regulates apolipoprotein e expression and secretion in neurons and astrocytes

Journal of Alzheimer's Disease

Volumn 51, Issue 2, 2016, Pages 471-487

  Xu, He ^a,b   Perreau, Victoria M ^a   Dent, Krista A ^a   Bush, Ashley I ^a   Finkelstein, David I ^a   Adlard, Paul A ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apolipoprotein E; iron; lipoprotein receptor related protein; low density lipoprotein receptor

Indexed keywords

APOLIPOPROTEIN E; IRON; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; AMYLOID BETA PROTEIN; COPPER; FERRITIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LRP1 PROTEIN, MOUSE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TUMOR SUPPRESSOR PROTEIN; ZINC;

ANIMAL CELL; ARTICLE; ASTROCYTE; ASTROCYTE CULTURE; BRAIN CELL; BRAIN CELL CULTURE; ENDOCYTOSIS; IN VITRO STUDY; IRON OVERLOAD; MOUSE; NONHUMAN; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BRAIN CORTEX; C57BL MOUSE; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; METABOLISM; NERVE CELL; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; ASTROCYTES; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; COPPER; FERRITINS; IMMUNOHISTOCHEMISTRY; IRON; MICE, INBRED C57BL; NEURONS; POLYMERASE CHAIN REACTION; REACTIVE OXYGEN SPECIES; RECEPTORS, LDL; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS; ZINC;

EID: 84961792801     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150797     Document Type: Article

References (74)

1. Singh N, Haldar S, Tripathi AK, Horback K, Wong J, Sharma D, Beserra A, Suda S, Anbalagan C, Dev S, Mukhopadhyay CK, Singh A. (2014). Brain iron homeostasis: From molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal 20, 1324-1363.
2. Sipe JC, Lee P, Beutler E. (2002). Brain iron metabolism and neurodegenerative disorders. Dev Neurosci 24, 188-196.
3. Ayton S, Lei P, Adlard PA, Volitakis I, Cherny RA, Bush AI, Finkelstein DI. (2014). Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: Implications for Parkinson's disease. Mol Neurodegener 9, 27.
4. Bilgic B, Pfefferbaum A, Rohlfing T, Sullivan EV, Adalsteinsson E. (2012). MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 59, 2625-2635.
5. Langkammer C, Ropele S, Pirpamer L, Fazekas F, Schmidt R. (2014). MRI for iron mapping in Alzheimer's disease. Neurodegener Dis 13, 189-191.
6. Peters DG, Connor JR, Meadowcroft MD. (2015). The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin. Neurobiol Dis 81, 49-65.
7. Lee JY, Cho E, Kim TY, Kim DK, Palmiter RD, Volitakis I, Kim JS, Bush AI, Koh JY. (2010). Apolipoprotein E ablation decreases synaptic vesicular zinc in the brain. Biometals 23, 1085-1095.
8. Bush AI. (2013). The metal theory of Alzheimer's disease. J Alzheimers Dis 33(Suppl 1), S277-S281.
9. Greenough MA, Camakaris J, Bush AI. (2013). Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem Int 62, 540-555.
10. Bertram L, Tanzi RE. (2009). Genome-wide association studies in Alzheimer's disease. Hum Mol Genet 18, R137-R145.
11. Lahiri DK, Sambamurti K, Bennett DA. (2004). Apolipoprotein gene and its interaction with the environmentally driven risk factors: Molecular, genetic and epidemiological studies of Alzheimer's disease. Neurobiol Aging 25, 651-660.
12. Bu G. (2009). Apolipoprotein E and its receptors in Alzheimer's disease: Pathways, pathogenesis and therapy. Nat Rev Neurosci 10, 333-344.
13. Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, Dee Fish J, Wyss-CorayT, Buttini M, MuckeL, MahleyRW, Huang Y. (2004). Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 24, 2527-2534.
14. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW. (2001). CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354-1357.
15. Pfrieger FW. (2003). Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci 60, 1158-1171.
16. Han SH, Kim JS, Lee Y, Choi H, Kim JW, Na DL, Yang EG, Yu MH, Hwang D, Lee C, Mook-Jung I. (2014). Both targeted mass spectrometry and flow sorting analysis methods detected the decreased serum apolipoprotein E level in Alzheimer's disease patients. Mol Cell Proteomics 13, 407-419.
17. Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, Lui JK, Masters C, Rowe CC, SzoekeC, Taddei K, Martins RN. (2011). Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging. Neurology 76, 1091-1098.
18. Bales KR. (2010). Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease. Neuropharmacology 59, 295-302.
19. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. (1991). Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541, 163-166.
20. Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM. (2013). ApoE influences amyloid-beta. (Abeta). clearance despite minimal apoE/Abeta association in physiological conditions. Proc Natl Acad Sci U S A 110, E1807-E1816.
21. Holtzman DM, Herz J, Bu G. (2012). Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2, a006312.
22. Rebeck GW, LaDu MJ, Estus S, Bu G, Weeber EJ. (2006). The generation and function of soluble apoE receptors in the CNS. Mol Neurodegener 1, 15.
23. Herz J, Strickland DK. (2001). LRP: A multifunctional scavenger and signaling receptor. J Clin Invest 108, 779-784.
24. Herz J, Kowal RC, Goldstein JL, Brown MS. (1990). Proteolytic processing of the 600kd low density lipoprotein receptor-related protein. (LRP). occurs in a trans-Golgi compartment. EMBO J 9, 1769-1776.
25. Vazquez-Higuera JL, Mateo I, Sanchez-Juan P, Rodriguez- Rodriguez E, Pozueta A, Infante J, Berciano J, Combarros O. (2009). Genetic interaction between tau and the apolipoprotein E receptor LRP1 Increases Alzheimer's disease risk. Dement Geriatr Cogn Disord 28, 116-120.
26. Rodriguez E, Mateo I, Llorca J, Sanchez-Quintana C, Infante J, Berciano J, Combarros O. (2006). Genetic interaction between two apolipoprotein E receptors increases Alzheimer's disease risk. J Neurol 253, 801-803.
27. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V. (2012). Association of ApoE and LRP mRNA levels with dementia and AD neuropathology. Neurobiol Aging 33, 628 e621-628 e614.
28. Taylor AM, Rhee SW, Tu CH, Cribbs DH, Cotman CW, Jeon NL. (2003). Microfluidic Multicompartment Device for Neuroscience Research. Langmuir 19, 1551-1556.
29. Adlard PA, Bica L, White AR, Nurjono M, Filiz G, Crouch PJ, Donnelly PS, Cappai R, Finkelstein DI, Bush AI. (2011). Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. PLoS One 6, e17669.
30. Chen SH, Lin JK, Liu SH, Liang YC, Lin-Shiau SY. (2008). Apoptosis of cultured astrocytes induced by the copper and neocuproine complex through oxidative stress andJNKactivation. Toxicol Sci 102, 138-149.
31. Wang XF, Cynader MS. (2001). Pyruvate released by astrocytes protects neurons from copper-catalyzed cysteine neurotoxicity. J Neurosci 21, 3322-3331.
32. White AR, Huang X, Jobling MF, Barrow CJ, Beyreuther K, Masters CL, Bush AI, Cappai R. (2001). Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: Possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem 76, 1509-1520.
33. Aimo L, Oteiza PI. (2006). Zinc deficiency increases the susceptibility of human neuroblastoma cells to lead-induced activator protein-1 activation. Toxicol Sci 91, 184-191.
34. Lei P, Ayton S, Appukuttan AT, Volitakis I, Adlard PA, Finkelstein DI, Bush AI. (2015). Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. Neurobiol Dis 81, 168-175.
35. Ghosh MC, Zhang L, Rouault TA. (2015). Iron misregulation and neurodegenerative disease in mouse models that lack iron regulatory proteins. Neurobiol Dis 81, 66-75.
36. Hare DJ, Grubman A, Ryan TM, Lothian A, Liddell JR, Grimm R, Matsuda T, Doble PA, Cherny RA, Bush AI, White AR, Masters CL, Roberts BR. (2013). Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry. Metallomics 5, 1656-1662.
37. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. (2014). The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13, 1045-1060.
38. Miyata M, Smith JD. (1996). Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-Amyloid peptides. Nat Genet 14, 55-61.
39. Dorey E, Chang N, Liu QY, Yang Z, Zhang W. (2014). Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease. Neurosci Bull 30, 317-330.
40. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. (2014). The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13, 1045-1060.
41. Poynton C, Jenkinson M, Adalsteinsson E, Sullivan E, Pfefferbaum A, Wells W. (2015). Quantitative susceptibility mapping by inversion of a perturbation field model: Correlation with brain iron in normal aging. IEEE Trans Med Imaging 34, 339-353.
42. Ramos P, Santos A, Pinto NR, Mendes R, Magalhaes T, Almeida A. (2014). Iron levels in the human brain: A post-mortem study of anatomical region differences and age-related changes. J Trace Elem Med Biol 28, 13-17.
43. Bush AI. (2003). The metallobiology of Alzheimer's disease. Trends Neurosci 26, 207-214.
44. LeVine SM, Wulser MJ, Lynch SG. (1998). Iron quantification in cerebrospinal fluid. Anal Biochem 265, 74-78.
45. Bishop GM, Robinson SR, Liu Q, Perry G, Atwood CS, Smith M.A. (2002). Iron: A pathological mediator of Alzheimer disease'. Dev Neurosci 24, 184-187.
46. Jiang D, Li X, Williams R, Patel S, Men L, Wang Y, Zhou F. (2009). Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: Binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease. Biochemistry 48, 7939-7947.
47. Ayton S, Faux NG, Bush AI. (2015). Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nat Commun 6, 6760.
48. Poirier J, Miron J, Picard C, Gormley P, Theroux L, Breitner J, Dea D. (2014). Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease. Neurobiol Aging 35(Suppl 2), S3-S10.
49. Fryer JD, Demattos RB, McCormick LM, O'DellMA, Spinner ML, Bales KR, Paul SM, Sullivan PM, Parsadanian M, Bu G, Holtzman DM. (2005). The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem 280, 25754-25759.
50. Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM. (2004). ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem 279, 40987-40993.
51. Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL. (2004). Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem 279, 41197-41207.
52. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. (2008). Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 118, 671-682.
53. Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G. (2007). Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56, 66-78.
54. Zarow C, Victoroff J. (1998). Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. Exp Neurol 149, 79-86.
55. Huang Y, Mahley RW. (2014). Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol Dis 72 Pt A 3-12.
56. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW. (2001). Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tanglelike intracellular inclusions in neurons. Proc Natl Acad Sci U S A 98, 8838-8843.
57. Jones PB, Adams KW, Rozkalne A, Spires-Jones TL, Hshieh TT, Hashimoto T, von Armin CA, Mielke M, Bacskai BJ, Hyman BT. (2011). Apolipoprotein E: Isoform specific differences in tertiary structure and interaction with amyloid-beta in human Alzheimer brain. PLoS One 6, e14586.
58. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. (1993). Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 11, 575-580.
59. Rapp A, Gmeiner B, Huttinger M. (2006). Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. Biochimie 88, 473-483.
60. Arelin K, Kinoshita A, Whelan CM, Irizarry MC, Rebeck GW, Strickland DK, Hyman BT. (2002). LRP and senile plaques in Alzheimer's disease: Colocalization with apolipoprotein E and with activated astrocytes. Brain Res Mol Brain Res 104, 38-46.
61. Spuch C, Ortolano S, Navarro C. (2012). LRP-1 and LRP-2 receptors function in the membrane neuron. Trafficking mechanisms and proteolytic processing in Alzheimer's disease. Front Physiol 3, 269.
62. Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtzman DM, Bu G. (2006). Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J Biol Chem 281, 36180-36186.
63. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. (2009). Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64, 632-644.
64. Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM. (2012). Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes. J Biol Chem 287, 13959-13971.
65. Li Y, Marzolo MP, Van Kerkhof P, Strous GJ, Bu G. (2000). The YXXL motif, but not the two NPXY motifs, serves as the dominant endocytosis signal for low density lipoprotein receptor-related protein. J Biol Chem 275, 17187-17194.
66. Rebeck GW, Moir RD, Mui S, Strickland DK, Tanzi RE, Hyman BT. (2001). Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP. Brain Res Mol Brain Res 87, 238-245.
67. Zerbinatti CV, Wozniak DF, Cirrito J, Cam JA, Osaka H, Bales KR, Zhuo M, Paul SM, Holtzman DM, Bu G. (2004). Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Natl Acad Sci U S A 101, 1075-1080.
68. Guo LY, Alekseev O, Li Y, Song Y, Dunaief JL. (2014). Iron increases APP translation and amyloid-beta production in the retina. Exp Eye Res 129, 31-37.
69. Kim CH, Yoo YM. (2013). Altered APP carboxyl-terminal processing under ferrous iron treatment in PC12 cells. Korean J Physiol Pharmacol 17, 189-195.
70. Avramovich-Tirosh Y, Amit T, Bar-Am O, Weinreb O, Youdim MB. (2008). Physiological and pathological aspects of Abeta in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators. BMC Neurosci 9. (Suppl). 2, S2.
71. Bandyopadhyay S, Huang X, Cho H, Greig NH, Youdim MB, Rogers JT. (2006). Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator. J Neural Transm Suppl 237-247.
72. Rogers JT, Bush AI, Cho HH, Smith DH, Thomson AM, Friedlich AL, Lahiri DK, Leedman PJ, Huang X, Cahill CM(2008). Iron and the translation of the amyloid precursor protein. (APP). and ferritin mRNAs: Riboregulation against neural oxidative damage in Alzheimer's disease. Biochem Soc Trans 36, 1282-1287.
73. Hass S, Fresser F, Kochl S, Beyreuther K, Utermann G, Baier G. (1998). Physical interaction of ApoE with amyloid precursor protein independent of the amyloid Abeta region in vitro. J Biol Chem 273, 13892-13897.
74. Huang Y. (2010). Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol Med 16, 287-294.